E-LIB Suche - Ergebnisse für: De Bruin, Marie L.

1

Regulatory, health technology assessment and company intera..:

Wang, Ting ; McAuslane, Neil ; Goettsch, Wim G...
International Journal of Technology Assessment in Health Care. 39 (2023) 1 - p. , 2023

Link: https://doi.org/10.1017/..

2

Duration of Effectiveness Evaluation of Additional Risk Min..:

Essink, Sharon C. M. ; Zomerdijk, Inge M. ; Straus, Sabine M. J. M...
Drug Safety. 46 (2023) 10 - p. 1007-1020 , 2023

Link: https://doi.org/10.1007/..

3

Influence of drug safety advisories on drug utilisation: an..:

Morrow, Richard L ; Mintzes, Barbara ; Souverein, Patrick C...
BMJ Quality & Safety. 31 (2022) 3 - p. 179-190 , 2022

Link: https://doi.org/10.1136/..

4

Mandatory requirements for pediatric drug development in th..:

Christiansen, Helle ; De Bruin, Marie L. ; Hallgreen, Christine E.
Frontiers in Medicine. 9 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

5

Guidance for pediatric use in prescription information for ..:

Christiansen, Helle ; De Bruin, Marie L. ; Frokjaer, Sven..
PLOS ONE. 17 (2022) 4 - p. e0266353 , 2022

Link: https://doi.org/10.1371/..

6

Hydroxyzine Initiation Following Drug Safety Advisories on ..:

Morrow, Richard L. ; Mintzes, Barbara ; Souverein, Patrick C....
Drug Safety. 45 (2022) 6 - p. 623-638 , 2022

Link: https://doi.org/10.1007/..

7

Challenges and Opportunities for Companies to Build HTA/Pay..:

Wang, Ting ; McAuslane, Neil ; Goettsch, Wim G...
Frontiers in Pharmacology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

8

Major bleeding in users of direct oral anticoagulants in at..:

van den Ham, Hendrika A. ; Souverein, Patrick C. ; Klungel, Olaf H....
Pharmacoepidemiology and Drug Safety. 30 (2021) 10 - p. 1339-1352 , 2021

Link: https://doi.org/10.1002/..

9

Advanced therapy medicinal product manufacturing under the ..:

Coppens, Delphi G.M. ; Hoekman, Jarno ; De Bruin, Marie L....
Cytotherapy. 22 (2020) 10 - p. 592-600 , 2020

Link: https://doi.org/10.1016/..

10

Pharmacogenetic‐Pharmacokinetic Interactions in Drug Market..:

Maliepaard, Marc ; Toiviainen, Timi ; De Bruin, Marie L..
Clinical Pharmacology & Therapeutics. 108 (2020) 2 - p. 338-349 , 2020

Link: https://doi.org/10.1002/..

11

Postmarket Safety Communication for Protection of Public He..:

Bhasale, Alice L. ; Sarpatwari, Ameet ; De Bruin, Marie L....
Clinical Pharmacology & Therapeutics. 109 (2020) 6 - p. 1424-1442 , 2020

Link: https://doi.org/10.1002/..

12

Comparing risk of major bleeding between users of different..:

Souverein, Patrick C. ; van den Ham, Hendrika A. ; Huerta, Consuelo...
British Journal of Clinical Pharmacology. 87 (2020) 3 - p. 988-1000 , 2020

Link: https://doi.org/10.1111/..

13

Adjusting for unmeasured confounding using validation data:..:

Hjellvik, Vidar ; De Bruin, Marie L. ; Samuelsen, Sven O....
Statistics in Medicine. 38 (2019) 15 - p. 2719-2734 , 2019

Link: https://doi.org/10.1002/..

14

Postauthorization Changes to Specific Obligations of Condit..:

Bloem, Lourens T. ; Mantel‐Teeuwisse, Aukje K. ; Leufkens, Hubert G. M....
Clinical Pharmacology & Therapeutics. 105 (2018) 2 - p. 426-435 , 2018

Link: https://doi.org/10.1002/..

15

EU decision-making for marketing authorization of advanced ..:

de Wilde, Sofieke ; Coppens, Delphi G.M. ; Hoekman, Jarno...
Drug Discovery Today. 23 (2018) 7 - p. 1328-1333 , 2018

Link: https://doi.org/10.1016/..